AI assistant
REGENXBIO Inc. — Director's Dealing 2026
Jan 8, 2026
32827_dirs_2026-01-08_9e908930-1517-4a0e-8504-cbd80718f631.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2026-01-06
Reporting Person: Malzahn Craig (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-06 | Common Stock | A | 65847.00 | $0.00 | Acquired | 82194.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | Stock Options (Right to buy) | $14.18 | A | 35402.00 | Acquired | 2036-01-06 | Common Stock (35402.00) | Direct |
Footnotes
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.
F2: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.